Dr Roopinder Gillmore

Job title

Consultant medical oncologist



GMC Number


Contact details

PA/secretary phone number: 020 7830 2601

PA/secretary email address: kdavis2@nhs.net

Fax: 020 7794 3341

Related services

Cancer services


Dr Gillmore is a consultant medical oncologist with a special interest in the treatment of pancreas and biliary tract cancers, working closely with the surgeons and radiotherapists.  She has established and leads the cancers of unknown primary service.  She is actively involved in clinical trials research. 


  • Suarez Martinez-Falero B and Gillmore R. A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. BMJ Case Reports April 2014
  • Gillmore, R and Sin, Wing Yee Chris.  Systemic lupus erythematosis mimicking lymphoma: The relevance of the clinical background in interpreting imaging studies.  BMJ Case Reports Jan 2014.
  • John BJ, Naik P, Ironside A, Davidson BR, Fusai G, Gillmore R, Watkins J, Rahman SH. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford). 2013 Sep;15(9):674-80. Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, Harrison M, Wasan H, Corrie P, Valle J. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer. 2013 Apr;49(6):1511. 
  • Pericleous M, Lumgair H, Baneke A, Morgan-Rowe L, Caplin M, Luong TV, Thirlwell C, Gillmore R, Toumpanakis C.  Appendiceal goblet cell carcinoid tumour: a case of unexpected lung metastasis.  Case Rep Oncol.  2012 May 5 (2) 332-8
  • Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T.EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation.  J Hepatol. Apr 2011
  • Gillmore R, Laurence V, Raouf S, Tobias J, Blackman G, Meyer T, Goodchild K, Collis C, Bridgewater J.  Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreas cancer; a UK multi-institutional experience.  Clin Oncol. 2010 Sept; 22(7):564-9.
  • Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T. Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin (FCiSt) for neuroendocrine tumors. Br J Cancer. 2010. Mar 30; 102 (7): 1106-12.
  • Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ.  Development of a WT1-TCR for clinical trials: engineered patients T cells can eliminate autologous leukaemia blasts in NOD/SCID mice. Haematologica. 2010: Jan 95 (1) 126-34.
  • King JW, Thomas S, Corsi F, Gao L, Dina R, Gillmore R, Pigott K, Kaisary A, Stauss HJ, Waxman J. IL-15 can reverse the unresponsiveness of Wilms’ Tumour Antigen specific CTL in Patients with Prostate Cancer. Clin Cancer Res. 2009. Feb 15: 15(4); 1145-54.
  • Gillmore R and Miles D. Angiogenesis and breast cancer. Advances in breast cancer. 2007 June; 4(2):48-50.
  • Gillmore R, Xue S, Holler A, Kaeda J, Hadjiminas D, Healy V, Dina R, Parry SC, Bellantuono I, Ghani Y, Coombes RC, Waxman J, Stauss HJ. Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res. 2006 Jan 1;12(1):34-42.
  • Mazhar D, Gillmore R, Waxman J. COX and cancer. QJM. 2005 Oct;98(10):711-8.
  • Xue S, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss HJ. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005 Nov 1;106(9):3062-7. 
  • Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ. Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol. 2005 Feb;139(2):167-72.
  • Xue S, Gao L, Gillmore R, Bendle G, Holler A, Downs A, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Stauss HJ, Morris E. WT1-targeted immunotherapy of leukaemia. Blood Cells Mol Dis. 2004 Nov-Dec;33(3):288-90.
  • Xue S, Gillmore R, Gao, L, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Morris E, Stauss HJ. Use of the allogeneic TCR repertoire to enhance anti-tumor immunity. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):131-3.
  • Seckl MJ, Gillmore R, Foskett M, Sebire NJ, Rees H, Newlands ES. Routine terminations of pregnancy--should we screen for gestational trophoblastic neoplasia? Lancet. 2004 Aug 21;364(9435):705-7.
  • Stauss HJ, Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Morris E. Exploiting alloreactivity for tumour immunotherapy. Vox Sang. 2004 Jul;87 Suppl 2:227-9
  • Gillmore R. Managing prostate cancer. Practitioner. 2004 Apr;248(1657):274-80.
  • Palmieri C, Gillmore R, Menzies-Gow A, Fishpool S, Robinson D, Shaw R, Coombes RC. Resolution of late-onset asthma following high-dose chemotherapy. Bone Marrow Transplant. 2003 Oct;32(8):847-8.
  • Harrison N, Mazhar D, Gillmore R, Waxman J. Dural metastasis in prostate cancer. Uro-oncology, 2003 Jun; 3 (2): 85-91       
  • Kendall A, Gillmore R, Newlands E. Chemotherapy for trophoblastic disease: current standards. Expert Rev Anticancer Ther. 2003 Feb;3(1):48-54.
  • Kendall A, Gillmore R, Newlands E. Chemotherapy for trophoblastic disease: current standards. Curr Opin Obstet Gynecol. 2002 Feb;14(1):33-8.